Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities in SCD, but distributional CEA (DCEA) uses equity weights to incorporate these considerations. OBJECTIVE: To compare gene therapy versus standard of care (SOC) in patients with SCD by using conventional CEA and DCEA. DESIGN: Markov model. DATA SOURCES: Claims data and other published sources. TARGET POPULATION: Birth cohort of patients with SCD. TIME HORIZON: Lifetime. PERSPECTIVE: U.S. health system. INTERVENTION: Gene therapy at age 12 years versus SOC. OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER) (in dollars per quality-adjusted life-years [QALYs] gained) and threshold inequality aversion parameter (equity weight). RESULTS OF BASE-CASE ANALYSIS: Gene therapy versus SOC for females yielded 25.5 versus 15.7 (males: 24.4 vs. 15.5) discounted lifetime QALYs at costs of $2.8 million and $1.0 million (males: $2.8 million and $1.2 million), respectively, with an ICER of $176 000 per QALY (full SCD population). The inequality aversion parameter would need to be 0.90 for the full SCD population for gene therapy to be preferred per DCEA standards. RESULTS OF SENSITIVITY ANALYSIS: SOC was favored in 100.0% (females) and 87.1% (males) of 10 000 probabilistic iterations at a willingness-to-pay threshold of $100 000 per QALY. Gene therapy would need to cost less than $1.79 million to meet conventional CEA standards. LIMITATION: Benchmark equity weights (as opposed to SCD-specific weights) were used to interpret DCEA results. CONCLUSION: Gene therapy is cost-ineffective per conventional CEA standards but can be an equitable therapeutic strategy for persons living with SCD in the United States per DCEA standards. PRIMARY FUNDING SOURCE: Yale Bernard G. Forget Scholars Program and Bunker Endowment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanders, G. D., Neumann, P. J., Basu, A., Brock, D. W., Feeny, D., Krahn, M., Kuntz, K. M., Meltzer, D. O., Owens, D. K., Prosser, L. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.12195 · Cited by 3,069
Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249 · cited 1×
“The ICERs were $178000 and $174000 per QALY for females and males, respectively, which exceeded the willingness-to-pay threshold of $100000 per QALY that is commonly used in conventional CEA in the United States (25).”
BackgroundCrizanlizumab for the prevention of pain crises in sickle cell disease.
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611770 · Cited by 914 · cited 1×
“L-glutamine and crizanlizumab effectively decrease the burden of vaso-occlusive crises for patients with SCD, and voxelotor increases hemoglobin levels (8, 9, 11).”
BackgroundPost-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease
Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029392 · Cited by 449 · cited 2×
“Age at treatment, y 12 12 to 50* Range from clinical trials (12, 13)”
MethodBiologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
Kanter, J., Walters, M. C., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Rifkin-Zenenberg, S., Aygun, B., Kasow, K. A., Pierciey, F. J., Bonner, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117175 · Cited by 442 · cited 2×
“Age at treatment, y 12 12 to 50* Range from clinical trials (12, 13)”
MethodSelf-citationLubeck, D., Agodoa, I., Bhakta, N., Danese, M., Pappu, K., Howard, R., Gleeson, M., Halperin, M., & Lanzkron, S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.15374 · Cited by 336 · cited 2×
“Annual background mortality probabilities specific to age, sex, race or ethnicity, and disease for patients living with SCD under the SOC strategy were informed by a cohort simulation model of patients in the United States that compared life expectancy in a prevalent SCD cohort with that of a matched cohort of persons…”
BackgroundMethod
Cited by
Basu, A., Winn, A. N., Johnson, K. M., Jiao, B., Devine, B., Hankins, J. S., Arnold, S. D., Bender, M. A., & Ramsey, S. D. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1520 · Cited by 28
Herring, W. L., Gallagher, M. E., Shah, N., Morse, K., Mladsi, D., Dong, O. M., Chawla, A., Leiding, J. W., Zhang, L., Paramore, C., et al. (2024) · PharmacoEconomics · doi:10.1007/s40273-024-01385-9 · Cited by 18
Kazi, D. S., Abdullah, A. R., Arnold, S. V., Basu, A., Bellows, B. K., Breathett, K., Chew, D. S., Cohen, D. J., DeJong, C., Heidenreich, P. A., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.05.009 · Cited by 14
Self-citation
Metadata
- Authors
- Goshua, G., Calhoun, C., Ito, S., James, L. P., Luviano, A., Krishnamurti, L., & Pandya, A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2023-06
- Volume
- 176
- Issue
- 6
- Pages
- 779-787
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4378672824
- Cited by
- 41
- References
- 6
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. https://app.cochat.ai/papers/10.7326/m22-3272
- The paper
- Goshua, G., Calhoun, C., Ito, S., James, L. P., Luviano, A., Krishnamurti, L., & Pandya, A. (2023). Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals of Internal Medicine. https://doi.org/10.7326/m22-3272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.